Related Experiment Videos
Digoxin is effective, but is it safe?
1University of Arizona College of Medicine, Tucson.
Insights
Digitalis effectively treats heart failure symptoms and improves function, but its safety after myocardial infarction is questionable, potentially increasing mortality. Careful consideration of digitalis administration is crucial.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Digitalis has demonstrated efficacy in managing congestive heart failure symptoms and improving cardiac function over the past 15 years.
- Clinical trials consistently show reduced hospitalizations for heart failure patients treated with digitalis.
Purpose of the Study:
- To evaluate the safety profile of digitalis, specifically concerning mortality rates.
- To investigate the association between digitalis use and increased mortality following acute myocardial infarction.
Main Methods:
- Review of double-blind, placebo-controlled clinical trials.
- Analysis of experimental data and clinical evidence.
- Statistical adjustment for predictor covariants and comorbidity.
Main Results:
- Digitalis use is linked to decreased heart failure symptoms, reduced hospitalizations, and improved cardiac function.
- Evidence suggests a potential increase in mortality associated with digitalis, particularly within the first two years post-myocardial infarction.
- This increased mortality risk persists even after statistical adjustments for comorbidities.
Conclusions:
- The safety of digitalis, especially after acute myocardial infarction, remains a significant concern.
- Physicians must carefully weigh the indications for prescribing digitalis in patients with a history of myocardial infarction.
- Enhanced patient surveillance is necessary during chronic digitalis therapy.
Abstract:
In the last 15 years several double-blind, placebo-controlled clinical trials have unequivocally shown that digitalis decreases symptoms of cardiac failure, results in a reduction in the need for hospitalization for treatment of congestive heart failure, and improves cardiac function. The major unresolved question concerning digitalis use is its safety. There are experimental data and clinical evidence that digitalis use may be associated with an increased mortality, particularly in the first year or two after an acute myocardial infarction. This increased mortality appears to be present even after adjustment for predictor covariants. This conclusion depends on the ability of statistical methods to account for differences in comorbidity. Since the question of digitalis safety remains after myocardial infarction, the physician should carefully examine the indications for administration of digitalis. More than the usual surveillance is required during chronic digitalis administration.